Key Takeaway
Use our free BMI calculator to check your GLP-1 eligibility. Find out if you qualify for semaglutide or tirzepatide treatment in minutes.
Medically reviewed by Dr. James Park, MD, PhD (Chief Science Officer, Johns Hopkins-trained, 28 published papers
Wondering if you qualify for GLP-1 treatment? This BMI calculator GLP-1 eligibility resource covers the important information you need to make informed decisions. A BMI calculator for GLP-1 eligibility is the fastest way to find out. Body mass index (BMI) is one of the first things a provider looks at when evaluating you for medications like semaglutide or tirzepatide.
Key Takeaways: - Learn how bmi determines glp-1 eligibility - Understand what the bmi categories mean for treatment - Beyond BMI: Other Factors Providers Consider - Learn how to use the bmi calculator and next steps
But BMI alone doesn't tell the whole story. Your overall health profile matters too. This guide walks you through how BMI connects to GLP-1 eligibility and what to expect during the qualification process.
How BMI Determines GLP-1 Eligibility
BMI measures your body weight relative to your height. It gives providers a quick snapshot of where you fall on the weight spectrum. For GLP-1 medications, clinical guidelines generally look for one of two thresholds.
A BMI of 30 or higher qualifies you in most cases. This falls into the "obesity" category on the BMI scale. If your BMI is between 27 and 29.9, you may still qualify if you have at least one weight-related health condition. These conditions include type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea.
Your provider will review your full medical history during a consultation. BMI is the starting point, not the finish line. Factors like previous weight loss attempts, family history, and current medications all play a role in the decision.
"We now have cardiovascular outcomes data showing semaglutide reduces MACE events by 20% in people with obesity, independent of diabetes status. The SELECT trial[1] changed how we think about these medications.") Dr. A. Michael Lincoff, MD, Cleveland Clinic, lead author of SELECT
To calculate your BMI, divide your weight in pounds by your height in inches squared, then multiply by 703. Or simply use our free BMI calculator to get your number instantly.
Free Download: Dose Conversion Table Get a quick-reference dose conversion table for common GLP-1 and peptide measurements. Handy for understanding your prescription. Get yours free (we'll email it to you instantly.
[Download Now]
What the BMI Categories Mean for Treatment
Understanding where you land on the BMI scale helps you prepare for your provider conversation. Here is a quick breakdown of the standard categories.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
A BMI under 18.5 is considered underweight. GLP-1 medications aren't appropriate here since these drugs promote weight loss. A BMI between 18.5 and 24.9 is the "normal" range. GLP-1 treatment is generally not prescribed at this level for weight management purposes.
A BMI between 25 and 26.9 is classified as overweight. Most guidelines don't support GLP-1 prescribing at this level unless there are specific clinical reasons. A BMI of 27 to 29.9 is also overweight, but this range opens the door to GLP-1 eligibility when combined with a qualifying health condition.
A BMI of 30 or above puts you in the obesity category. This is where most GLP-1 prescriptions begin. Clinical trials for both semaglutide and tirzepatide enrolled participants with BMIs in this range and showed significant results.
Keep in mind that BMI has limitations. It doesn't account for muscle mass, bone density, or body composition. Athletes and people with higher muscle mass may have improved BMIs without excess body fat. Your provider will consider these factors during evaluation.
Ready to check your number? Take our free 2-minute eligibility quiz to see if GLP-1 treatment may be right for you.
Beyond BMI: Other Factors Providers Consider
Your BMI opens the door, but providers look at the full picture before prescribing GLP-1 medications. Here are the key factors they evaluate during a consultation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Medical history plays a major role. Providers want to know about conditions like thyroid disorders, pancreatitis, or a history of medullary thyroid cancer. These may affect whether GLP-1 medications are safe for you. A family history of certain conditions matters too.
Current medications can interact with GLP-1 drugs. If you take insulin, sulfonylureas, or other diabetes medications, your provider may need to adjust dosages. Be prepared to share a complete list of everything you take, including supplements.
Previous weight loss attempts help providers understand your treatment. Many insurance plans and clinical guidelines look for evidence that you have tried other approaches first. This might include diet programs, exercise plans, or other medications.
Lab work may be requested. Blood sugar levels, A1C, liver function, and kidney function tests give your provider important data points. These results help ensure that GLP-1 treatment is both safe and appropriate for your situation.
Your mental health and relationship with food also factor in. Providers want to make sure you have realistic expectations and a support system in place. GLP-1 medications work best as part of a complete plan that includes nutrition and lifestyle changes.
How to Use the BMI Calculator and Next Steps
Using our BMI calculator takes less than 30 seconds. Enter your height and weight, and the tool instantly shows your BMI along with your eligibility category.
If your results suggest you may qualify, the next step is a provider consultation. FormBlends connects you with licensed providers who specialize in weight management and GLP-1 prescribing. The process is simple and done entirely online.
During your consultation, your provider will review your BMI, health history, and goals. If approved, you'll receive a personalized compounded medication prepared by a licensed US-based 503A pharmacy. Your treatment plan will include a titration schedule that gradually increases your dose over time.
You can track your progress using the FormBlends app, which includes dose logging, weight tracking, and medication level visualization. Many users find that tracking their experience keeps them motivated and helps them stay on schedule.
Frequently Asked Questions
What BMI do I need for GLP-1 medication?
Most guidelines require a BMI of 30 or higher. If your BMI is between 27 and 29.9, you may qualify if you also have a weight-related condition like type 2 diabetes, high blood pressure, or high cholesterol. Your provider makes the final determination.
Is BMI the only factor for GLP-1 eligibility?
No. BMI is the starting point, but providers also evaluate your medical history, current medications, lab work, and previous weight loss efforts. The full picture determines whether GLP-1 treatment is appropriate for you.
Can I use GLP-1 medications if my BMI is in the normal range?
GLP-1 medications are generally not prescribed for weight management when BMI is below 27. But some GLP-1 drugs are approved for type 2 diabetes management regardless of BMI. Talk to your provider about your specific situation.
How accurate is BMI as a health measure?
BMI is a useful screening tool but has limitations. It doesn't distinguish between muscle mass and body fat. Athletes or muscular individuals may have higher BMIs without excess fat. Your provider will consider body composition and other health markers alongside BMI.
How quickly can I start GLP-1 treatment after checking my BMI?
If you qualify, FormBlends can connect you with a provider within days. After your consultation, medication is typically shipped directly to you from a licensed pharmacy. Many patients begin treatment within one to two weeks of their initial consultation.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide) no pressure, no commitment.
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →